Sign In
Buy MBOT
$1.72
-0.0200 (-1.15%)
At Close: Jul 31, 2026
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician i
Stryker to Report Q1 Earnings: What's in Store for the Stock?
09:50am, Tuesday, 28'th Apr 2026
SYK heads into Q1 earnings with strong procedure demand and robotic surgery growth, but tariff and cost pressures may test margins.
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY
Microbot Medical Begins Full U.S. Launch of LIBERTY System
01:36pm, Wednesday, 15'th Apr 2026
MBOT moves to full U.S. launch of its LIBERTY robotic system after strong hospital adoption, boosting momentum for faster market uptake and sales growth.
The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum The presentation will be webcast live on April 15 at 10:1
HINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has
World's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases perfor
Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-
Microbot Medical® to Participate at the 38th Annual Roth Conference
08:40am, Tuesday, 17'th Mar 2026
HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will parti
Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
08:30am, Tuesday, 10'th Mar 2026
HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be pa
Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Rating of “Moderate Buy” from Analysts
04:46am, Saturday, 07'th Mar 2026
Shares of Microbot Medical Inc. (NASDAQ: MBOT - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat.com reports. One analys
LIBERTY® Endovascular Robotic System's Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers LIBERTY® Endovascular Robotic System's Capability to Reduce Radiation Exp
Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
09:00am, Tuesday, 03'rd Mar 2026
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Com
Tampa General Hospital Adopts Small-Cap Microbot Medical's Robotic System
01:48pm, Tuesday, 24'th Feb 2026
Microbot Medical's recent achievement comes on the heels of its FDA 510(k) clearance for the LIBERTY system, which is designed for precision in peripheral endovascular procedures.
